New drug cocktail aims to outsmart tough cancers
NCT ID NCT04028063
Summary
This study is testing whether adding two newer immunotherapy drugs to a standard chemotherapy drug (doxorubicin) can help control advanced soft tissue sarcoma for longer. It will enroll about 65 adults with specific types of this cancer who have not had certain prior treatments. The main goal is to see if more people are free from cancer growth at 6 months compared to historical results from chemotherapy alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOFT TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Colorado Hospital
RECRUITINGAurora, Colorado, 80045, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.